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Abstract 
Objective: To identify a novel biochemical marker that precedes clinical 
symptoms of Alzheimer’s disease (AD). 
Methods: Using quantitative PCR techniques, we measured circulating cell free 
mitochondrial DNA (mtDNA) in cerebrospinal fluid (CSF) from study 
participants, selected from a cohort of 282 subjects, that were classified, 
according to their concentrations of Aβ1-42, t-tau and p-tau and by the presence 
or absence of dementia, in: asymptomatic subjects at risk of AD, symptomatic 
patients diagnosed with sporadic AD, pre-symptomatic subjects carrying 
pathogenic PSEN1 mutations and patients diagnosed with Fronto-temporal 
Lobar Degeneration (FTLD). We performed equivalent studies in a separate 
validation cohort of sporadic AD and FTLD patients. In addition, we measured 
mtDNA copy number in cultured cortical neurons from mutant Amyloid 
Precursor Protein/Presenilin1 (APP/PS1) transgenic mice.  
Results.  Asymptomatic patients at risk of AD, and symptomatic AD patients, 
but not FTLD patients, exhibit a significant decrease in circulating cell free 
mtDNA in the CSF. These observations were confirmed in the validation cohort. 
In addition, pre-symptomatic subjects carrying pathogenic PSEN1 gene 
mutations show low mtDNA content in CSF before the appearance of AD 
related biomarkers in CSF. Moreover, mtDNA content in CSF classifies with 
high sensitivity and specificity AD patients against either controls or patients 
with FTLD. Furthermore, cultured cortical neurons from APP/PS1 transgenic 
mice have less mtDNA copies, before the appearance of altered synaptic 
markers. 
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Interpretation:  Low content of mtDNA in CSF may be a novel biomarker for 
the early detection of preclinical AD. These findings support the hypothesis that 
mtDNA depletion is a characteristic pathophysiological factor of 
neurodegeneration in AD. 
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Introduction 
Recent evidence indicates that AD is preceded by a long preclinical 
phase with abnormal biochemical, structural and functional changes in the 
brain, suggesting that the pathophysiological process of neurodegeneration in 
AD starts well before the appearance of clinical signs of dementia. There are 
two biochemical markers, currently accepted to precede the appearance of 
clinical symptoms of dementia, that are widely used to define preclinical AD: 1) 
Brain accumulation of Amyloid β (Aβ) or low Aβ1-42 content in CSF, and 2) 
Elevated CSF total tau (t-tau) and phosphorylated-tau (p-tau)1,2. Low 
concentrations of Aβ1-42 in CSF are associated with AD3,4 and correlate with 
accumulation of Aβ in the brain5,6. High CSF concentrations of t-tau and p-tau 
are associated with increased neocortical neurofibrillary tangles in AD affected 
brains at autopsy7. When used in combination, these two biomarkers support a 
good predictive value for negative AD diagnosis4, but the diagnosis of AD is still 
probabilistic and requires the presence of clinical symptoms. The mechanistic 
relationship between the alteration of Aβ or tau biomarkers and the appearance 
of clinical signs of AD still remains elusive. Thus, brain amyloidosis appears to 
be necessary but not sufficient to produce the clinical signs of AD because post-
mortem studies indicate that a considerable amount (10-30%) of people without 
dementia exhibit this neuropathological hallmark of AD 8,9. Hence, the 
identification of new biomarkers that precede the appearance of clinical 
symptoms is crucial to advance in the knowledge of the pathophysiology of AD 
and for the development of therapeutic treatments.  
CSF is in direct contact with brain parenchyma and it is considered to be 
the optimal fluid to identify possible alterations of brain metabolism10. However, 
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the relationship between brain and CSF levels of proteins in AD is not 
straightforward because the levels of CSF proteins such as tau correlate 
positively, while others such as Aβ correlate negatively with accumulation in 
brain. The reason why accumulation of Aβ in the brain is associated with low 
concentrations of Aβ1-42 in the CSF is unclear, although it may be due to a 
decreased clearance of Aβ1-42 from the brain to the CSF11. In contrast, a high 
concentration of t-tau in CSF is considered to reflect neuronal injury associated 
with accumulation of tau in the brain. However, other tauopathies in which there 
is high brain accumulation of tau in neurofibrillary tangles, do not exhibit a 
corresponding increase in CSF t-tau12. Puzzled with the opposite relationship 
between CSF and brain levels of Aβ and t-tau in AD, we initiated the search for 
new CSF biomarkers to gain further knowledge on the pathophysiological 
mechanisms of AD. 
Converging evidence indicates that AD is associated with alterations in 
bioenergetics and mitochondrial function 13,14. Neurons are highly dependent on 
aerobic energy provided by mitochondria, which contain several copies of their 
own DNA (mtDNA). Differently from genomic DNA, the covalently closed 
circular form of mtDNA renders it more resistant to degradation by nucleases, 
possibly present in the CSF. Because there are multiple copies of mtDNA per 
cell and mitochondria are distributed along axons, nerve terminals and dendritic 
arbors next to dendritic spines, we thought that the potential release of mtDNA 
to the extracellular space might be an index of mtDNA turnover in the brain. For 
this reason, we decided to explore whether it is possible to detect cell free 
mtDNA in the CSF using polymerase chain reaction techniques (PCR), which 
provide a relatively higher sensitivity and specificity than those offered by 
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currently available antibody-based protein detection procedures. We 
hypothesized that if cell free mtDNA could be detected in CSF, then mtDNA 
levels would reflect alterations in brain metabolism and might represent an early 
indicator of the neurodegenerative process in AD.  
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Methods 
Subjects 
The study subjects were selected from a cohort of 282 subjects recruited 
at the Alzheimer's disease and other cognitive disorders Unit of the Hospital 
Clinic of Barcelona. All subjects underwent clinical and neuropsychological 
assessment and lumbar puncture. Subjects were classified according to their 
concentrations of Aβ1-42, total amount of microtubule-associated protein tau (t-
tau), phosphorylated tau in threonine 181 (p-tau) and by the presence or 
absence of dementia (Table 1 and Supplementary Tables S1 and S2). Six 
groups were selected for the study: 1) AD, patients diagnosed with probable AD 
using NINCDS/ADRDA’s criteria15 and with the typical CSF biomarker profile 
characteristic of AD: low levels of Aβ1-42 and elevated levels of t-tau and p-tau; 
2) Low Aβ, asymptomatic subjects at risk to develop AD that do not have 
cognitive deficits and only have low CSF Aβ1-42; 3) FTLD, symptomatic patients 
diagnosed with any of the syndromes incorporated within the Fronto-temporal 
Lobar Degeneration classification including progressive non-fluent aphasia, 
fronto-temporal dementia or semantic dementia, but with normal AD-related 
CSF biomarkers. 4) PSEN1, pre-symptomatic patients carrying a dominant 
PSEN1 mutation (M139T, K239N or I439S) with normal CSF biomarkers and 
normal cognition; 5) C1, age matched control group consisting of healthy 
subjects without cognitive deficits and normal CSF biomarkers to serve as 
control group for Low Aβ and AD groups; 6) C2, age-matched control group for 
PSEN1 mutation carriers composed by subjects of their family without clinical, 
genetic or biochemical AD related alterations. The following pathologic cut-off 
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values were used: Aβ1-42 <500 pg/mL; t-tau >450 pg/mL; and p-tau >75 pg/mL. 
The subjects in all groups were finally balanced to avoid significant age 
differences between the groups . Only subjects <75 years of age were included 
in this study because of the lack of healthy controls without any altered 
biomarker above this age. Finally, samples with signs of blood contamination or 
from subjects with a CSF level of total protein above 0.7 mg/ml, were excluded 
from the study. 
 
CSF samples 
All CSF samples were obtained with informed consent at the Alzheimer’s 
Disease and other cognitive disorders Unit of the Neurology Service, following 
the procedure approved by the ethics committee of the Hospital Clinic of 
Barcelona. The CSF samples were obtained by lumbar puncture between 9 
a.m. and 12 p.m. A small initial volume of CSF was set aside to measure the 
presence of cells and perform other biochemical measurements and this was 
followed by collection of 10 ml of CSF. To prevent contamination of CSF with 
blood cells possibly acquired in the process of lumbar puncture, CSF samples 
were centrifuged immediately after collection at 2000 g for 10 min at 4ºC and 
stored within two hours after extraction in polypropylene tubes at −80 °C. 
Biomarkers Aβ1–42, t-tau and p-tau were measured by enzyme-linked 
immunosorbent assay kits (Innogenetics, Ghent, Belgium). Subsequent PCR 
amplification with primers targeting the high copy nuclear gene 18S ribosomal 
RNA showed that the CSF samples used in our experiments do not contain 
nuclear DNA above the detection limit of 0.6 genomes per sample, ruling out 
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the possibility of CSF contamination with DNA from peripheral cells in the 
samples used for PCR studies. 
 
Real time quantitative PCR 
We could not find previous evidence showing the presence of circulating 
cell free mtDNA in human CSF. Hence, we first studied whether cell free 
circulating mtDNA can be detected in human CSF samples and next assessed 
its concentration by real time quantitative PCR with a standard calibration curve 
following MIQE guidelines16. Reactions were performed with at least ten 
replicates on Corbett Rotor-Gene 6000 (Corbett, Mortlake, NSW, 2137, 
Australia). Each 20 l PCR reaction consisted of 1X SsoFast EvaGreen (Bio-
Rad Laboratories, Hercules, CA 94547, USA), 300 nM forward/reverse primers 
and 6.2 l of CSF sample. To detect mtDNA in the CSF, we designed PCR 
primers which amplify a region between bases 14418 and 14932 that encodes 
the mitochondrial genes ND6, tRNA-Glu and CYTB, according to the 
Cambridge reference sequence for human mitochondrial DNA (RefSeq: 
NC_012920.1). We choose only primers that are not associated with known 
single nucleotide polymorphisms. To confirm the specificity of the DNA 
amplified in the PCR reaction we designed three different combinations of 
primers targeting the same region of mtDNA (Fig 1A and B). Primer sequences 
5’-3’ are: F1- CCCCTGACCCCCATGCCTCA, R1- 
GCGGTGTGGTCGGGTGTGTT, F2- CTCACTCCTTGGCGCCTGCC, R2- 
GGCGGTTGAGGCGTCTGGTG. One primer combination, F1-R2, was 
designed to amplify a long 515 bp region (mtDNA-515). Two other primer pairs 
(F1-R1, F2-R2) were designed to amplify two short sequences (153 and 85 bp, 
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mtDNA-153 and mtDNA-85, respectively) that are within the long 515 bp region 
(Fig 1A). To verify the detection of mtDNA in CSF, we used another PCR 
technique based on hydrolysis probes with a primer combination targeting a 
different mitochondrial gene. For these studies, each 20ul PCR reaction 
consisted of 1X SsoFast Probes Supermix (Bio-Rad Laboratories, Hercules, CA 
94547, USA), 100 nM forward/reverse primers, 125 nM Probe (5’-FAM-
TGCCAGCCACCGCG-MGB-3’) and 6.2 ul of CSF sample. The primers for this 
PCR reaction were designed to amplify a region between bases 805 and 927 of 
mtDNA genome that encodes the 12S mitochondrial ribosomal RNA gene. The 
sequences of this primer combination producing a 123 bp amplicon (mtDNA-
123) are: Forward, 5’-CCACGGGAAACAGCAGTGAT-3’; Reverse, 
5’CTATTGACTTGGGTTAATCGTGTGA-3’. 
mtDNA may accumulate oxidative or structural damage and the longer 
the amplicon the higher the likelihood to have damaged bases that would 
prevent its amplification by the polymerase during the PCR reaction17. The PCR 
amplification of two different short sequences by the first two sets of primers 
(mtDNA-85 and mtDNA-153) was intended to confirm the specificity of the 
mtDNA target. The amplification of the longer sequence (mtDNA-515) was 
planned to assess the influence of mtDNA structural damage in the PCR 
reaction and as a further confirmation of mtDNA target specificity. The 
conditions for quantitative PCR were optimized using melting curve analysis to 
ensure the presence of a single amplification product. The characteristics of the 
amplified product were analyzed by both melting curve analysis and gel 
electrophoresis. Amplification was performed using the following cycle 
conditions: 95⁰C, 2 min followed by 45 cycles at 95⁰C, 5 s, and 65⁰C, 10s, 20s 
11 
 
or 60s for mtDNA-85, mtDNA-153 and mtDNA-515 respectively. Quantification 
Cycle (Cq) measurements were set within the exponential range. 
Quantification of cell free mtDNA in the CSF was performed with a 
standard calibration curve of human mtDNA purified from HEK293T cells. 
Human purified mtDNA was obtained from mitochondria isolated by subcellular 
fractionation and Percoll gradient. Mitochondria were isolated from 1x107 
HEK293T cells. Cells were washed, harvested in 2 ml of isolation buffer (20mM 
Hepes, 300mM Sucrose, 1mM EDTA, 1mM DTT, pH 7.4), and homogenized in 
a Glass/Teflon Potter-Elvehjem tissue grinder. The crude homogenate was 
centrifuged once at 1000g for 10 min to remove unbroken cells and nuclei. The 
crude mitochondria-containing supernatant was layered over a 23/15/10/3 % 
(v/v) discontinuous Percoll gradient in isolation buffer and centrifuged at 
31.000g (Sorvall, FiberLite F21 rotor) for 5 mins at speed. The fraction 
containing mitochondria located between 15 and 23% Percoll layers was 
transferred to 1.5 ml microcentrifuge tubes and diluted 1:1 (v:v) in isolation 
buffer. After gentle mixing, mitochondria were centrifuged at 20000g for 20 min. 
The supernatant was discarded and DNA was extracted from the mitochondrial 
pellet using an alkaline lysis protocol (Wizard Plus Miniprep, Promega, 
Madison, WI, USA). The content of mtDNA in the mitochondrial DNA extract 
was assessed by different methods: a) by qPCR with three primer combinations 
against a standard curve of the respective amplicon cloned in pJET1.2 plasmid; 
b) by ddPCR.  The concentration of mtDNA in CSF was calculated based on the 
assumption that one copy of mtDNA corresponds to 18.16 ag. Characterization 
studies indicated that mtDNA can be detected in human CSF samples in a 
range between 29-35 Cq, corresponding to a range of 2-300 fg/ml. Accordingly, 
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the concentration range of the standard calibration curve of mtDNA used in our 
experiments was 1-200 copies of mtDNA per reaction. PCR reaction efficiency 
was higher than 0.95 in all runs. 
 
CSF ultrafiltration 
Initially, we observed that direct mtDNA amplification in CSF samples 
produced PCR reactions with low efficiency (Supplementary Fig S1), indicating 
that CSF contains molecules that inhibit the detection of DNA by PCR, which 
compromise accurate quantification, as has been previously reported for other 
quantitative PCR assays in human body fluids. To achieve an accurate 
quantification of mtDNA, we performed several treatments of the CSF to 
remove PCR inhibitors and obtain PCR efficiencies equivalent to those obtained 
in our purified mtDNA standard. We found that ultrafiltration of the CSF 
completely removed PCR inhibitors yielding a PCR reaction efficiency 
equivalent to the observed in the mtDNA standard (Supplementary Fig S1) and 
indicating that the inhibitory substances present in CSF are soluble and of low 
molecular weight. CSF samples were ultrafiltrated using Amicon Ultra 0,5ml 
filters (Millipore, MA, USA) with 10000 MWCO. The samples were diluted 10 
times the initial volume with PCR-grade water and concentrated back to the 
initial volume by centrifugation at 14000g for 10min. This ultrafiltration 
procedure was performed twice.  
 
Droplet digital PCR 
To validate results obtained with real time qPCR, we performed 
additional quantification of cell free circulating mtDNA in CSF samples from 
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some groups of the study cohort (Table 1 and Supplementary Table S2) by 
droplet digital PCR using Bio-Rad QX100 Digital Droplet PCR platform (Bio-Rad 
Laboratories, Hercules, CA 94547, USA). mtDNA was amplified directly in CSF 
samples with a FAM labeled probe and with the F1 and R1 primers that produce 
the mtDNA-153 amplicon used in the previous real time qPCR analyses. The 
reaction consisted of 1X ddPCR  Mastermix, F1 and R1 primers at 900nM and a 
FAM labeled probe at 250nM. Probe sequence was 6-carboxyfluorescein 
(FAM)-5’-CGCTGTAGTATATCCAAAGACAACCATCATTCCCCC-3’-Black Hole 
Quencher-1 (BHQ-1). Droplet emulsion formation was performed by mixing 20ul 
reaction with 60ul droplet generation oil using a microfluidic droplet generation 
cartridge and QX100 Droplet Generator. The saturating PCR amplification was 
performed using C1000 Thermal Cycler with the following conditions. 95ºC 
10min; 40 repeats of 94ºC 30sec 59ºC 1min; 98ºC 10min. PCR conditions were 
previously optimized using mtDNA purified from HEK293T cells. The presence 
or absence of amplification per droplet was evaluated using QX100 Droplet 
Reader (FAM channel) and analyzed using QuantaSoft protocol. The results 
were expressed in copies of mtDNA per l of CSF. 
 
Separate validation cohort: Subjects and qPCR methods 
A separate validation cohort was collected to perform a replication study 
using a different qPCR method. The validation cohort was limited to sporadic 
AD and FTLD and consists of subjects recruited at the Neurology Service of the 
Hospital de Sant Pau of Barcelona and additional subjects recruited after the 
end of our first study at the Hospital Clinic of Barcelona (Table 1 and 
Supplementary Table S3). All subjects underwent clinical and 
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neuropsychological assessment and CSF samples were obtained by lumbar 
puncture with informed consent following the methods and rules approved by 
the ethics committee of the respective hospital of origin. Subjects were 
classified according their concentrations of CSF Aβ1-42, t-tau, p-tau and by the 
presence or absence of dementia with the same inclusion criteria and 
pathological cut-off values used for the study cohort. Content of mtDNA was 
measured directly in CSF with an improved qPCR reaction procedure that 
circumvents the need of previous sample ultrafitration and with a new primer 
combination (mtDNA-73) which targets an mtDNA region different than the one 
targeted in the first study (Table 2). Reactions were performed with at least four 
replicates. The PCR reaction was in a final volume of 45.4 l and consisted of 
1X SsoFast EvaGreen (Bio-Rad Laboratories, Hercules, CA 94547, USA), 300 
nM forward/reverse primers and 2 l of CSF sample. The mtDNA-73 PCR 
primer pair amplifies a region between bases 13699 and 13771 that encodes 
the mitochondrial gene ND5, according to the Cambridge reference sequence 
for human mitochondrial DNA (RefSeq: NC_012920.1). The sequences of this 
primer combination producing an amplicon 73 bp long are: Forward, 5’- 
AAACGCCTGGCAGCCGGAAG-3’; Reverse, 5’ 
GGAAGGGGGATGCGGGGGAA-3’. Amplification was performed using the 
following cycle conditions: 95⁰C, 2 min followed by 45 cycles at 95⁰C, 5 s, and 
60⁰C, 8s. Quantification of cell free mtDNA in the CSF was performed using an 
improved reference standard curve consisting of a known amount of copies of 
the plasmid pJET1.2 containing the mtDNA-73 amplicon. PCR reaction 
efficiency was higher than 0.95 in all runs. 
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Cortical Neuronal Culture  
Primary cultures of cortical neurons were prepared from E17 embryo 
brain cortices from B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax (APP/PS1) 
(Jackson Laboratories, Bar Harbor, ME, USA) mice of either sex. Cells were 
dissociated in the presence of trypsin and DNaseI and plated in poly-D-lysine 
(100 g/ml)-coated dishes at a density of 2 x 105 cells/cm2 in neurobasal 
medium supplemented with 2% B27, 0.1 mg/ml gentamicin, 0.5 mM glutaMAX. 
One third of the media volume was changed every 3-4 days. Cells were 
maintained at 37 ºC in a humidified incubator with 5% CO2 and 95% air. The 
cultures were left in vitro undisturbed until the day (DIV) of the experiments. All 
procedures involving animals and their care were approved by the ethics 
committee of the University of Barcelona and they were conducted in 
accordance with guidelines that conform with national (Generalitat de 
Catalunya) and international laws and policies (Guide for the Care and Use of 
Laboratory Animals, National Academy Press, Washington, DC, 1996). 
 
Genotyping of mice  
Tail DNA was obtained following the protocol of The Jackson Laboratory 
(Bar Harbor, Maine, USA). 1 mm of tail was cut and incubated at 55 ºC in a 
buffer containing 50 mM KCl, 10 mM Tris.HCl pH 8.3, 2.5 mM MgCl2•6H2O, 
0.45% (v/v) Nonidet P40, 0.45% (v/v) Tween 20 and 150 g/ml Proteinase K 
(Gibco). After tissue digestion, the samples were incubated for 5 min at 95 ºC to 
inactivate Proteinase K and 2 l of this sample were used for PCR analysis. 
Animals were genotyped by multiplex PCR using SSo Advanced Supermix (Bio-
Rad Laboratories) with primers targeting the APP transgene and the IL-II gene 
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as a positive control. The primers were APP: Forward, 5’- 
CATAGCAACCGTGATTGTCATC-3’and Reverse, 5’-
TGGATTCTCATATCCGTTCTGC-3’; IL-II: Forward, 5’- 
CTAGGCCACAGAATTGAAAGATCT -3’and Reverse, 5’- 
GTAGGTGGAAATTCTAGCATCATCC -3’. PCR conditions were: 2 min at 98 °C 
initial denaturation, followed by 45 cycles of 5s of denaturation at 98°C, 30s of 
primer annealing and extension at 60°C. Genotype was determined by melting 
curve analysis of PCR products. 
 
Determination of mtDNA copy number in cultured cortical neurons 
Total DNA was extracted by incubating cortical cultured neurons with 
SDS buffer (100 mM Tris-HCL, 10mM EDTA, 0.5% SDS, 20 g/ml RNAse A, 
pH 8.0) for 1 h at 37º C in a extraction volume of approximately 1 l per 1000 
cells. Lysates were incubated with Proteinase K (100 g/ml) for 1 h at 56º C 
followed by 10 mins at 95º C to inactivate the enzyme. Quantitative PCR was 
performed directly in extraction buffer to minimize the loss of mtDNA in column 
purification procedures 18. We found that extraction buffer diluted 1:500 does 
not inhibit the efficiency of the PCR reaction. For mtDNA amplification, we used 
two primer combinations amplifying nested amplicons located within bases 214 
to 912 of the 12S ribosomal RNA from of Mus musculus mitochondrion 
complete genome NC_005089.1: mtDNA-115 and mtDNA-699, producing 
amplicons of 115 and 699 base pairs, respectively. Each reaction contained 10 
l 2X SsoAdvanced Supermix (Bio-Rad Laboratories, Hercules, CA 94547, 
USA), 0.3 M of each primer and 10 l of 1:250 dilution of extracted sample for 
a final volume of 20 l. The primer sequences are: mtDNA-115 (forward, 5’-
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CTAGCCACACCCCCACGGGA-3’ and reverse, 5’-
CGTATGACCGCGGTGGCTGG-3’); mtDNA-699 (forward primer of mtDNA-115 
and reverse, 5’-CGGGCGGTGTGTGCGTACTT-3’). PCR conditions were: 2 
min at 95 °C initial denaturation, followed by 45 cycles of 5 s of denaturation at 
95 °C and 12 or 60 s of primer annealing/extension at 60ºC or 65ºC for mtDNA-
115 and mtDNA-699 respectively. For nuclear DNA (nDNA) quantification, we 
first amplified a sequence of 219 bp length of the nuclear multiple copy gene 
18S ribosomal RNA.  The primer sequences are: Forward, 5’-
CGCGGTTCTATTTTGTTGGT-3’ and Reverse, 5’- 
AGTCGGCATCGTTTATGGTC-3’. PCR conditions were: 2 min at 95 °C initial 
denaturation, followed by 45 cycles of 5 s of denaturation at 95 °C and 20 s of 
primer annealing/extension at 57ºC. All reactions were performed in triplicate.  
Quantification Cycle (Cq) measurements were set within the exponential range. 
Only reactions with efficiencies higher than 90% were considered. The absence 
of unspecific amplicons was confirmed by melting curve analysis and gel 
electrophoresis. Quantification of mtDNA and 18S ribosomal RNA nuclear DNA 
(nDNA) copies was obtained against a standard curve of the respective 
amplicons cloned in pJET1.2 plasmids. The results are expressed as mtDNA 
copies over 18S rRNA copies. In subsequent characterization experiments, we 
assessed the number of 18S rRNA copies present in the genome of cultured 
cortical neurons against a standard curve of two different single copy genes (IL-
II and NP1) amplicons cloned in pJET1.2 plasmids.  The results revealed that 
cultured cortical neurons have approximately 50 copies of 18S ribosomal RNA, 
indicating that these cells contain a range of 300-600 copies of mtDNA per cell. 
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Statistical Analysis 
Results are expressed as mean ± SEM.  The statistical significance of 
the differences was examined using Kruskal-Wallis test with Dunn’s post hoc 
multiple comparisons, one-way ANOVA with Bonferroni post hoc multiple 
comparisons tests or with Two-tailed unpaired Student’s t tests or Mann-
Whitney U tests when required. Receiver operating characteristic curve and 
area under the curve analyses were performed with GraphPad Prism software. 
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Results 
Detection of circulating cell free mtDNA in CSF 
First we examined whether cell free mtDNA can be detected in CSF. 
Characterization studies showed that mtDNA can be detected by PCR 
amplification in a small volume of human CSF (10 l) and that ultrafiltration of 
CSF removes inhibitory substances that prevent efficient PCR reactions and 
precise quantification (Supplementary Fig S1). To confirm the specificity of the 
amplified DNA, we used three different combinations of primers (Fig 1 and 
Table 2); one primer pair amplifying a long 515 bp region (mtDNA-515) and two 
other primer pairs, nested within this region, amplifying 85 bp (mtDNA-85) and 
153bp (mtDNA-153) respectively (Fig 1A and 1B). PCR reactions were 
performed in CSF samples with each one of the three primer combinations. To 
rule out the possibility of non specific amplification, and verify the presence of 
only one amplicon, all PCR reactions were tested by melting curve analysis. 
The melting curve of the PCR reaction product from each primer combination 
was similar in all samples analyzed, with the exception of samples from 
subjects #1 and #51. The PCR products of the three primer combinations from 
these subjects, from study subject # 2 (Fig 1B) and from some other study 
subjects were sequenced and found to correctly match the corresponding 
targeted reference sequence NC_012920.1 of the human mitochondrial 
genome, with the exception of PCR products from subjects #1 and #51 which 
showed a G to A mutation in base number 14905 (Table 2). These results 
indicate that the products amplified by our primer combinations in CSF 
effectively correspond to mtDNA present in the CSF from study subjects and 
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not from external sources. PCR amplification with primers targeting the high 
copy nuclear gene for 18S ribosomal RNA showed that the CSF samples used 
in our experiments do not contain nuclear DNA above the detection limit of 0,6 
genomes per sample, indicating that mtDNA we detected in CSF is cell free. To 
determine the concentration of mtDNA in CSF, we next performed real time 
quantitative PCR (qPCR) analyses in CSF samples, with an external standard 
consisting of a wide concentration range of purified human mtDNA isolated from 
HEK 293T cells. Results showed that mtDNA can be detected in human CSF in 
a range between 29-35 Cq, corresponding to concentrations of circulating 
mtDNA between 2-300 fg/ml. Equivalent results were obtained with a different 
qPCR analysis technique based on hydrolysis probes using a primer 
combination targeting a mtDNA region encoding the mitochondrial 12S 
ribosomal RNA gene (results not shown). No significant differences in CSF 
mtDNA levels were observed between males and females in any of the study 
groups (Fig S2). 
 
CSF mtDNA levels in asymptomatic subjects at risk and sporadic AD patients 
Next we analyzed the mtDNA content in CSF from subjects at the 
preclinical stage of AD, also named asymptomatic at risk, and from 
symptomatic sporadic AD patients (Table 1 and Supplementary Table S1). 
Amplification of the mtDNA-85 region revealed a marked reduction of cell free 
mtDNA content in CSF samples from both Low Aβ asymptomatic at risk 
subjects (LAβ=28±4 fg/ml, n=7) and symptomatic AD patients (AD=48±7 fg/ml, 
n=13), corresponding to a decrease of 85±2% and 74±3%, respectively, 
compared with the age matched control group 1 (C1=188±49 fg/ml, n=10). An 
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equivalent effect was observed when mtDNA concentration in CSF was 
assayed with the other two primer combinations. Thus, qPCR of mtDNA-153 
showed a reduction of CSF mtDNA content of 96±1% and 84±4% in LAβ (6±1 
fg/ml, n=7) and AD (23±6 fg/ml, n=13) groups, respectively, compared with the 
C1 group (142±44 fg/ml, n=10). Likewise, qPCR of the mtDNA-515 amplicon 
showed a reduction in CSF mtDNA content of 92±3% and 70±7% in LAβ (3±1 
fg/ml, n=7) and AD (11±3 fg/ml, n=13) groups respectively, compared with the 
C1 control group (37±4 fg/ml, n=10) (Fig 1C). The AD patient group tended to 
have higher mtDNA content in CSF than the LAβ group in all three primer 
combinations, but this difference was not statistically significant. Overall, no 
significant differences were observed amongst groups in the percentage of 
decrease of mtDNA amplification between the longest amplicon (mtDNA-515) 
and the short amplicons (mtDNA-85 and mtDNA-153). Low mtDNA amplification 
could indicate either low mtDNA copy number or loss of DNA integrity. In the 
latter case, it is expected that the longer the amplicon the higher the reduction 
of PCR amplification, because long amplicons are more likely to accumulate 
damaged bases that would prevent its amplification by the polymerase. The 
equivalent reduction of mtDNA amplification observed in the present studies 
with amplicons of different length indicates that the decrease in mtDNA in LAβ 
and AD groups reflects a decrease in mtDNA copy number rather than a 
difference in mtDNA integrity. In summary, these results show that cell free 
mtDNA content in the CSF is reduced before the appearance of clinical 
symptoms, suggesting that low mtDNA is associated with the risk to develop 
AD. 
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CSF mtDNA levels in FTLD patients 
To assess whether this decrease in the CSF content of mtDNA is also 
present in other non Alzheimer type dementias, we measured mtDNA 
concentration in CSF from symptomatic patients diagnosed with FTLD (Table 1 
and Supplementary Table S1) 19.  Real time qPCR analysis revealed that 
mtDNA concentration in the CSF from these patients, as measured by the three 
different primer combinations (mtDNA-85= 132±35 fg/ml, mtDNA-153=234±160 
fg/ml and mtDNA-515=77±27 fg/ml; n=15), was not significantly different from 
that found in C1 controls; but it was significantly higher than the observed in 
LAβ and AD groups (Fig 1C), indicating that AD and FTLD dementia do not 
share this decrease in cell free mtDNA concentration in CSF.  
 
CSF mtDNA levels in preclinical subjects with PSEN1 mutations 
To explore whether low mtDNA content in the CSF is present at the early 
preclinical stages of AD, we studied the CSF content of mtDNA in young pre-
symptomatic subjects with a mutation causing AD before they reach a stage in 
which they have alterations in AD related biomarkers. We quantified cell free 
mtDNA concentration in CSF from a young group of cognitively normal subjects 
that do not show any alteration in Aβ and tau biomarkers but carry a pathogenic 
PSEN1 mutation (M139T, K239N or I439S) that will cause the full emergence of 
clinical AD symptoms on average at least one decade later (Table 1).  Analysis 
of the CSF of these pre-symptomatic subjects also revealed a marked reduction 
in cell free mtDNA concentration in CSF, compared with the age matched 
control group. The magnitude of the reduction of mtDNA content in mutation 
carriers compared with controls was similar with the three different amplicons; 
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54±10% (PSEN1=27±6 fg/ml, n=6; C2=59±9 fg/ml, n=7), 68±11% 
(PSEN1=14±5 fg/ml, n=6; C2=43±12 fg/ml, n=7) and 66±11% (PSEN1=4±1 
fg/ml, n=5; C2=13±3 fg/ml, n=7) for mtDNA-85, mtDNA-153 and mtDNA-515, 
respectively (Fig 1D). The results obtained in these pre-symptomatic PSEN1 
subjects are consistent with those found in subjects at risk to develop AD (Fig 
1C) and provide more evidence to suggest that reduced concentration of 
mtDNA in the CSF is present in early preclinical stages of AD. In contrast with 
the decrease of mtDNA content in CSF from patient groups, we found that in all 
primer combinations, mtDNA content in CSF is significantly higher (p<0.01) in 
the older C1 control group (mtDNA-85=188±49, mtDNA-153=142±44 and 
mtDNA-515=37±4 fg/ml; n=10) compared to the younger C2 control group 
(mtDNA-85=59±9, mtDNA-153=43±12 and mtDNA-515=13±3 fg/ml, n=10) 
indicating that mtDNA concentration in CSF increases with age, a process that 
is opposite to what we find in preclinical and asymptomatic at risk AD patients. 
 
Receiver operating characteristic curve analysis of mtDNA CSF levels 
To determine whether the amount of mtDNA in CSF efficiently 
discriminates between patients with sporadic AD and controls or FTLD we 
performed receiver operating characteristic curve (ROC) analysis of relative 
values of cell free mtDNA in CSF normalized to % control from all three 
(mtDNA-85, mtDNA-153, mtDNA-515) primer pairs combined (Fig 2A and 2B). 
The results showed that using a cut-off value of <50%, low CSF content of 
mtDNA distinguishes the diagnosis of sporadic AD from age matched controls 
with a sensitivity of 92%, specificity of 90%, respectively, and area under ROC 
curve of 0.992 (95% confidence interval= 0.967-1), significantly higher than 
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random (p<0.001). Likewise, with a cut-off value of <50%, the content of CSF 
mtDNA discriminates between AD and FTLD with a sensitivity of 92%, 
specificity of 87% and area under ROC curve of 0.98 (95% confidence interval= 
0.957-1),  significantly higher than random (p<0.001). Similar results were 
obtained when ROC analyses of mtDNA content between the different groups 
were performed with absolute data in fg/ml, either separate or combined, from 
each of the mtDNA amplicons (results not shown). These results provide further 
evidence to suggest that low mtDNA content in the CSF is specially related with 
AD. 
 
Analysis of CSF mtDNA by ddPCR 
Next we sought to determine whether the differences in CSF content of 
mtDNA found in our previous experiments could be validated with droplet digital 
PCR (ddPCR), a novel method that has made recently possible to directly 
quantify nucleic acid content at a single molecule resolution of target sequence. 
One advantage of this new PCR technique is that it does not require previous 
processing of the sample because the presence of inhibitory molecules does 
not significantly influence digital PCR quantification. Measurement of mtDNA 
copy number in CSF with ddPCR using mtDNA-153 amplicon primers confirmed 
that symptomatic AD patients have significantly lower number of mtDNA copies 
in CSF (AD=18.3±3.8 copies/l, n=20) compared with the age matched control 
and FTLD groups (C1=41.8±7.9, n=9; FTLD=41.2±13.1, n=11, copies/l), 
corresponding to a decrease of 56±9% of mtDNA in AD patients compared with 
the C1 group (Fig 3). These results are qualitatively equivalent to those found 
using real time qPCR and confirm our previous data showing that the 
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concentration of mtDNA in CSF in patients diagnosed with probable AD is 
different from those diagnosed with FTLD. 
 
Analysis of CSF mtDNA in the separate validation cohort   
To assess whether the findings of our first study are influenced by cohort 
characteristics or technical factors, we performed additional research in 
samples from a separate validation cohort of asymptomatic at risk of AD 
subjects and symptomatic AD and FTLD patients (Table 1 and Supplementary 
Table S3). Measurement of mtDNA copy number directly in CSF using an 
improved qPCR procedure with the mtDNA-73 primer combination confirmed 
that there is a significant reduction of cell free mtDNA content in CSF from Low 
A asymptomatic at risk subjects (C-LAβ =44±8 copies/l, n=5) and 
symptomatic AD patients (C-AD=67±9 copies/l, n=17), corresponding to a 
decrease of  79±4 %  and  69±4%, respectively, compared with the age 
matched control group (C-C= 214±47 copies/l, n=19) (Fig 4A). No significant 
decrease in CSF mtDNA was observed in the C-FTLD group. These results are 
qualitatively equivalent to those obtained in the study cohort shown in Fig 1C. 
Moreover, in contrast with the study cohort, the validation cohort contains 
patients with two APOE 4/4  alleles. In this cohort, analysis of the relationship 
between APOE genotype and CSF mtDNA levels showed that the APOE 4 
allele is associated with low CSF concentration of mtDNA (Fig 4B). 
 
mtDNA copy number in cultured cortical neurons from APP/PS1 mice 
Previous evidence has shown that there is a decrease in mtDNA copy 
number in postmortem brain from patients with AD20, but in human brain tissue 
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it is not possible to determine when this effect starts and whether it is caused by 
the neurodegenerative process. To assess whether the decrease in the CSF 
concentration of mtDNA associated with AD occurs in the central nervous 
system before the appearance of neuronal damage, we measured the amount 
of mtDNA copies in cultured cortical neurons from transgenic mice expressing 
human APP/PS1 mutations. Neurons from these mice showed a significant 
decrease (~28%) of mtDNA copies per cell, as measured with two different 
primer combinations (Fig 5A). This decrease of mtDNA copy number occurs in 
cultured cortical neurons at 14 DIV well before the appearance of alterations in 
synaptic markers as measured by Synaptophysin and PSD95 protein levels (Fig 
5B to D). These results are consistent with the interpretation that the decrease 
in cell free mtDNA content found in CSF of AD patients reflects a low mtDNA 
copy number per cell in central nervous system neurons and that low mtDNA 
content appears early in the neurodegenerative process of AD.  
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Discussion 
Here we report that a decrease in the CSF concentration of circulating 
cell free mtDNA precedes the appearance of core AD biomarkers in the CSF of 
pre-symptomatic subjects who will develop AD. The reduction of mtDNA content 
found in the CSF of PSEN1 mutation carriers occurs at least one decade before 
these patients are expected to manifest clinical signs of dementia and appears 
before any change in the CSF levels of Aβ1-42, the first pathological sign known 
to be altered in the preclinical stage of AD. This suggests that the 
pathophysiological process of AD would start earlier than previously thought 
and that the content of mtDNA in the CSF, like some neuroimaging procedures, 
may be one of the earliest biomarkers of the long neurodegenerative course of 
the disease. Likewise to familial AD, we find that low mtDNA concentration in 
the CSF is also present in sporadic AD. Thus, depletion of CSF mtDNA occurs 
in patients diagnosed with probable sporadic AD as well as in asymptomatic 
subjects at risk to develop AD, before alterations in t-tau and p-tau. The finding 
that low mtDNA concentration is a common feature in the CSF of both pre-
symptomatic mutation carriers who will develop familial AD at an early age and 
asymptomatic subjects at risk to develop sporadic AD, suggests that mtDNA 
content in the CSF may help to detect early the preclinical stage of the disease. 
Moreover, we find that mtDNA content in CSF can distinguish patients 
diagnosed with AD from either control or patients with FTLD. Patients in each of 
these groups, as well as the corresponding control subjects, were carefully 
selected, to the detriment of the number of patients per group, according to the 
presence or absence of clinical, genetic and biomarker criteria to obtain the 
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highest possible homogeneity within experimental groups and avoiding any 
biomarker overlap amongst groups. The high efficiency and specificity that 
mtDNA content in CSF exhibits for the differential diagnosis of AD and FTLD, 
together with the observation that low mtDNA in CSF occurs in presymptomatic 
pathogenic PSEN1 mutation carriers well before the appearance of any clinical 
or biomarker signs, suggests that reduction of mtDNA content in CSF is a 
particular pathophysiological factor of AD. Moreover, the present results imply 
that the pathophysiology underlying AD type dementia is different from FTLD, 
which otherwise are often difficult to distinguish in terms of their clinical 
presentation. At present, we do not know if the decrease of mtDNA in CSF 
occurs also in other neurodegenerative disorders in addition to AD. As the 
recruitment of more voluntary controls and subjects at risk for other 
neurodegenerative disorders progresses, future studies will determine whether 
the decrease in mtDNA occurs in other neurodegenerative diseases. However, 
the finding that low content of CSF mtDNA occurs both in familial and sporadic 
forms of AD before the appearance of clinical symptoms, but not in symptomatic 
patients with dementia of the FTLD type, supports the interpretation that altered 
mtDNA replication or degradation is a key pathophysiological mechanism in the 
early stage of AD. 
The discovery that low CSF content of cell free circulating mtDNA is 
associated with sporadic AD and is already present in asymptomatic subjects at 
risk of AD was replicated in a separate validation cohort, which included 
samples obtained in another hospital. Moreover, in contrast with the study 
cohort, the validation cohort contains samples from patients with the APOE 
4/4 alleles, the main genetic risk factor for late onset AD. Interestingly, the 
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analysis of the relationship between APOE genotype and CSF mtDNA showed 
that the APOE 4 allele is associated with low CSF concentration of mtDNA. 
This might be because all subjects with the APOE 4/4 genotype fell in the AD 
group; we could not find subjects with this genotype in the other groups. 
However, the relationship between APOE 4 allele and mtDNA decline is 
consistent with the interpretation that CSF mtDNA concentration is an early 
indicator of the neurodegenerative process in AD. Although more long term 
studies in different laboratories with neuropathologically confirmed cases are 
necessary to validate whether mtDNA content in CSF is an early biomarker of 
AD, the present results suggest that mtDNA depletion is a fundamental 
biological process in the disease. 
It is well established that patients with AD exhibit significant neuronal 
death. Hence, the finding that preclinical subjects at risk of AD have lower 
mtDNA concentration in CSF appears to be contrary to what should be 
expected if the origin of mtDNA in the CSF is damaged brain neurons or broken 
cells from choroid plexus or periventricular zones. However, the present results 
support the interpretation that the amount of circulating mtDNA in the CSF, in 
the absence of cell damage, is related with the amount of mtDNA per cell. Thus, 
the low mtDNA content found in both asymptomatic subjects at risk of AD and 
pre-symptomatic mutation carriers that have not reached the stage of structural 
brain damage, is consistent with the hypothesis that brain cells of all these 
subjects have less mtDNA before significant signs of neurodegeneration. 
Actually, the results reported here are in agreement with recent evidence 
showing that postmortem brains from patients with AD exhibit low mtDNA copy 
number and impaired mitochondrial biogenesis 20,21, which supports the 
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interpretation that cell free circulating mtDNA content in the CSF is a reflection 
of the amount of mtDNA per cell in the brain. Moreover, the finding that 
depletion of mtDNA precedes alterations in synaptic markers in cultured cortical 
neurons from APP/PS1 mice (Fig 5) is consistent with the notion that changes 
in mtDNA content occur early in the neurodegenerative process. Furthermore, 
the finding that mtDNA content in CSF increases with age (Fig 1), which is 
opposite to what we find in preclinical AD, provides support to the notion that 
low mtDNA content in CSF is an index of a particular pathophysiological factor 
related with AD that occurs before neuronal cell damage. 
More studies are needed in both animal models and human therapeutic 
clinical assays to determine whether the reduction in cell free mtDNA content in 
CSF reported here mirrors an etiological factor of the neurodegenerative 
process in AD, and whether CSF mtDNA concentration may change with 
disease-modifying treatments. Longitudinal studies in human therapeutic trials 
to determine whether new disease –modifying treatments are capable of 
returning AD related protein biomarkers to normal levels are hampered by the 
technical difficulties associated with current antibody-based protein detection 
procedures. One important advantage of measuring mtDNA as an index of 
preclinical AD is that mtDNA can be detected by normal qPCR or by droplet 
digital PCR, facilitating the assessment of larger cohorts in longitudinal studies 
with higher sensitivity and specificity. CSF contains factors that inhibit the PCR 
reaction and these factors can be removed by ultrafiltration and not by 
treatment with proteinase K, indicating that the inhibitory molecules are not 
proteins. However, we found that PCR detection of mtDNA in CSF either after 
ultrafitration or directly in a very small non-inhibitory volume of CSF yields 
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qualitatively equivalent results. Direct measurement of CSF mtDNA by real time 
qPCR or by ddPCR may enable more laboratories to investigate the role of 
mtDNA in AD progression and widen the possibility to identify new treatments. 
We speculate that if the magnitude of the decrease of cell free mtDNA 
that we find in CSF directly reflects what happens in neurons it would likely be a 
causal factor for neurodegeneration by cellular energy deprivation, because 
neurons are highly dependent on aerobic energy provided by mitochondria. The 
finding that low mtDNA content occurs in the CSF from subjects at risk of both 
sporadic and familial forms of AD, but not in subjects with non-AD dementia, 
provides strong evidence to hypothesize that regulation of mtDNA copy number 
is a common mechanism onto which different pathways causing AD converge. 
In neurons, many different mechanisms that regulate mitochondrial function can 
cause depletion of mtDNA, and those can be either intrinsic to mitochondrial 
function, i.e oxidative stress, or extrinsic such as Aβ accumulation. Recent 
evidence showing that proteins that cause AD when mutated, such as PSEN1 
and PSEN2 complexes and APP, are associated with mitochondrial 
membranes22,23 and may regulate mitochondrial function is consistent with this 
hypothesis. The heuristic hypothesis that we propose here postulating that low 
mtDNA content in CSF is a pathophysiological biomarker of AD would integrate 
with the more general unifying hypothesis which proposes that the 
pathophysiology of AD is caused by bioenergetic decline due to mitochondrial 
dysfunction13,14,24. More research stemming from the hypothesis that low 
mtDNA concentration in CSF is associated with risk of AD may help the 
development therapeutic treatments and also to increase the knowledge of the 
pathophysiological mechanisms causing dementia in AD.  
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Table 1.  a) Subjects for the study cohort were selected from a cohort of 282 
subjects. b) Available CSF samples from the study cohort were used to 
determine CSF mtDNA copy number. Additional subjects were incorporated in 
the AD group. c) Groups of the validation cohort (C-) included 25 subjects 
recruited at the Neurology Service of the Hospital de Sant Pau of Barcelona and 
25 subjects recruited independently from the first study at the Hospital Clinic of 
Barcelona. d) CSF samples were classified according to the concentrations of 
Aβ1-42, t-tau and p-tau and by the presence or absence of dementia in the 
subjects.  C1: age matched control group consisting of healthy subjects without 
cognitive deficits and normal CSF biomarkers. LAβ: asymptomatic subjects at 
risk to develop AD that do not have cognitive deficits and only have low CSF 
Aβ1-42. AD: patients diagnosed with probable sporadic Alzheimer’s disease with 
low levels of Aβ1-42 and elevated levels of t-tau and p-tau. FTLD: patients 
diagnosed with Frontotemporal Lobar Degeneration and with normal AD-related 
CSF biomarkers. C2: age matched control group, which includes subjects 
without clinical, genetic or biochemical AD related alterations as a control for 
PSEN1 group. PSEN1: pre-symptomatic patients carrying a dominant 
pathogenic Presenilin 1 mutation (M139T, K239N or I439S) with normal CSF 
biomarkers and normal cognition. N=number of subjects per group. ** 
Significantly different from the corresponding control group (Oneway ANOVA 
with Bonferroni post-hoc comparisons, p<0.01).  
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Table 2. PCR reactions were performed in human CSF samples with each one 
of four primer combinations as described in Methods section. Each reaction was 
tested by melting curve analysis to rule out the possibility of non specific 
amplification and verify the presence of only one amplicon. The melting curve of 
the amplicons from each primer combination was the same in all samples, with 
the exception of samples from subjects #1 and #51 in primer combination F1-
R2 and subjects #80 and #93 in primer combination F3-R3. The PCR products 
of the four primer combinations obtained from these and other subjects 
(including the representative CSF amplicons from study subject #2. shown in 
Fig. 1B) were sequenced by dsDNA sequencing to verify that their sequence 
corresponds to human mtDNA. The sequence of the amplicons obtained in the 
first three primer combinations correctly matched the corresponding targeted 
reference sequence NC_012920.1 of the human mitochondrial genome in all 
samples analyzed, with the exception of the amplicons mtDNA-515 and mtDNA-
85 from subjects #1 and #51 that share a G to A mutation in base number 
14905. In all samples analyzed, the amplicon of mtDNA-73 differed in one base 
(A to T) from the reference mtDNA sequence.  
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Figure 1. Reduction of mitochondrial DNA concentration in cerebrospinal fluid 
from preclinical Alzheimer’s disease subjects.  Real time quantitative PCR was 
performed to measure mtDNA content in CSF samples with primers targeting a 
region between bases 14418 and 14932 of human mtDNA. A) Three different 
combinations of primers, two of them nested, were used to confirm specificity of 
mtDNA in the CSF by PCR amplification. Two sets of PCR primers (F1-R1, F2-
R2) were designed to amplify two short sequences (153 bp and 85 bp, mtDNA-
153 and mtDNA-85, respectively) located within a close distance of human 
mtDNA at the extremes of a longer, 515 bp (mtDNA-515) sequence, that could 
be amplified also by the combination of the forward and reverse primers of the 
first and second primer set respectively (F1-R2). B) Representative image of an 
agarose gel showing DNA size marker (M), mtDNA-153 (Lane 1), mtDNA-85 
(Lane 2) and mtDNA-515 (Lane 3) amplicons obtained with the three different 
primer pairs in a CSF sample from study subject number 2. C,D) Quantification 
of mtDNA content by real time PCR in CSF from asymptomatic subjects at risk, 
AD and FTLD patients (C) and pre-symptomatic PSEN1 mutation carriers (D). 
Values are mean ± SEM of mtDNA concentration in CSF expressed in fg/ml. 
The number above error bars represents the number of subjects per group. *, 
p<0.05; **, p<0.01, significantly different from the corresponding age matched 
control group (Kruskal-Wallis test with Dunn’s post-hoc comparisons). #, 
p<0.05, significantly different from the corresponding age matched control 
group (Mann-Whitney U test, two tailed). 
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Figure 2. Receiver operating characteristic curve analysis. Sensitivity and 
specificity of relative values of cell free mtDNA in CSF shown in Fig 1C, from all 
three (mtDNA-85, mtDNA.153, mtDNA-515) primer pairs combined and 
normalized to % control,  to correctly categorize patients with a diagnosis of: A) 
Cognitively normal age matched controls, C1 (n=10) versus Probable 
Alzheimer’s disease, AD (n=13); area under the curve = 0.992, p<0.001; B) 
Frontotemporal Lobar Degeneration with normal AD-related biomarkers, FTLD 
(n=15) versus Probable Alzheimer’s disease, AD (n=13); area under the curve= 
0.982, p<0.001. 
 
Figure 3. Quantification of cell-free mtDNA copies in CSF samples by ddPCR. 
mtDNA copy number was measured directly in CSF samples by droplet digital 
PCR using Bio-Rad QX100 Digital Droplet PCR platform. The mtDNA-153 
amplicon was obtained with F1 and R1 primers and a FAM labeled probe. 
Results were analyzed using QuantaSoft program. Values are expressed as 
mean ±SEM of number of mtDNA copies per l of CSF. C1, Age matched 
control group. AD, patients diagnosed with probable sporadic Alzheimer’s 
disease with low Aβ1-42 and high t-tau and p-tau CSF levels. FTLD, patients 
diagnosed with Frontotemporal Lobar Degeneration and with normal AD-related 
CSF biomarkers. The number above error bars represents the number of 
subjects per group. **, p<0.01, significantly different from C1 (Kruskal-Wallis 
test with Dunn’s post-hoc comparisons). 
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Figure 4. Analysis of mtDNA content and relationship with APOE genotype in 
CSF samples from a separate validation cohort of sporadic AD.  CSF was 
assayed directly in real time quantitative PCR reaction with the mtDNA-73 
primer combination targeting a region between bases 13699-13771 of human 
mtDNA. (A) mtDNA concentration expressed in number of copies/l in CSF 
from age matched controls (C-C), asymptomatic subjects at risk (C-LA) and 
symptomatic patients diagnosed with AD (C-AD) or FTLD patients (C-FTLD) of 
the validation cohort. (B) Analysis of the relationship between APOE genotype 
and mtDNA content in CSF. Values are mean ± SEM of mtDNA concentration in 
CSF expressed in copies/l. The number above error bars represents the 
number of subjects per group. *, p<0.05; **, p<0.01, significantly different from 
control group (Kruskal-Wallis test with Dunn’s post-hoc comparisons).  
 
Figure 5. Reduction of mtDNA copy number occurs before alterations in 
synaptic markers in cultured cortical neurons from APP/PS1 mice.  mtDNA copy 
number and synaptic proteins were measured in cultured cortical neurons from 
wildtype (WT) and APP/PS1 mice. A) mtDNA was measured in cultured cortical 
neurons at 14 DIV. Number of mtDNA  and 18S rRNA copies were determined 
against reference plasmids containing the amplified sequences. For mtDNA, 
two different primer combinations were used: mtDNA-115 and mtDNA-699, 
producing amplicons of 115 and 699 base pairs, respectively. Values are mean 
± SEM of n=number of animals, of mtDNA copies/copy of 18S rRNA. WT (n=8), 
APP/PS1 (n=16). *, p<0.05; **, p<0.01, significantly different from the 
corresponding control (Student’s unpaired t-test, two tailed). B) Representative 
western blots showing PSD95 and Synaptophysin (Syn) protein levels in 
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cultured cortical neurons lysates from WT and APP/PS1 mice at 14 and 21 DIV. 
Proteins were separated by SDS-PAGE and transferred to PVDF membranes. 
C-D) Quantitative analysis PSD95 and Synaptophysin protein levels. The 
densitometric values of the bands representing PSD95 (C) or Synaptophysin 
(D) immunoreactivity were normalized to the values of the corresponding actin 
band. Values are mean ± SEM for PSD95 (WT n=11 and 11; APP/PS1 n=9 
and10, for 14 and 21 DIV, respectively) and for Synaptophysin (WT n=12 and 
10; APP/PS1 n=9 and 10, for 14 and 21 DIV, respectively). **, p<0.01, 
significantly different from the corresponding control (Student’s unpaired t-test, 
two tailed). 
  
Table 1. Age and biomarker characteristics of subject groups in study and 
validation cohorts  
 
 
 
GROUPd N Age Aβ  
[pg/ml] 
t-tau  
[pg/ml] 
p-tau-T181 
[pg/ml] 
Study Cohorta: Groups analyzed by Real Time qPCR 
C1 10 62±1 883±73 226±15 52±3 
LAβ 7 67±3 364±32** 162±22 40±6 
AD 13 64±2 302±18** 883±125** 119±13** 
FTLD 15 61±2 718±40 268±27 47±3 
C2 7 38±3 690±25 261±17 53±1 
PSEN1 6 35±3 908±163 246±19 51±3 
Study Cohortb: Groups analyzed by ddPCR 
C1 9 62±1 885±81 227±17 52±3 
AD 20 65±1 328±14** 897±95** 123±10** 
FTLD 11 60±3 772±43 313±38 55±4 
Validation Cohortc: Groups analyzed by Real Time qPCR 
C-C1 19 61±1 808±41 207±10 49±3 
C-LAβ 5 67±4 419±37** 197±39 38±6 
C-AD 17 66±1 321±21** 833±80** 95±5** 
C-FTLD 9 60±2 734±37 234±24 42±2 
Table 2.  Sequences of Human mtDNA amplified by Real Time qPCR 
Primer 
Combination 
PCR 
Amplicon 
Human mtDNA Region 
Ref Seq: NC_012920.1 
Sequence 5'-3' 
 
F2-R2 
 
mtDNA-85 bp 
 
14848-14932 
CTCACTCCTTGGCGCCTGCCTGATCCTCCAAATCACCACAG
GACTATTCCTAGCCATG*CACTACTCACCAGACGCCTCAACC
GCC 
 
F1-R1 
 
 
mtDNA-153 bp 
 
 
14418-14570 
 
CCCCTGACCCCCATGCCTCAGGATACTCCTCAATAGCCATC
GCTGTAGTATATCCAAAGACAACCATCATTCCCCCTAAATAA
ATTAAAAAAACTATTAAACCCATATAACCTCCCCCAAAATTCA
GAATAATAACACACCCGACCACACCGC 
 
F1-R2 
 
 
mtDNA-515 bp 
 
 
14418-14932 
 
CCCCTGACCCCCATGCCTCAGGATACTCCTCAATAGCCATC
GCTGTAGTATATCCAAAGACAACCATCATTCCCCCTAAATAA
ATTAAAAAAACTATTAAACCCATATAACCTCCCCCAAAATTCA
GAATAATAACACACCCGACCACACCGCTAACAATCAATACTA
AACCCCCATAAATAGGAGAAGGCTTAGAAGAAAACCCCACA
AACCCCATTACTAAACCCACACTCAACAGAAACAAAGCATAC
ATCATTATTCTCGCACGGACTACAACCACGACCAATGATATG
AAAAACCATCGTTGTATTTCAACTACAAGAACACCAATGACC
CCAATACGCAAAACTAACCCCCTAATAAAATTAATTAACCAC
TCATTCATCGACCTCCCCACCCCATCCAACATCTCCGCATG
ATGAAACTTCGGCTCACTCCTTGGCGCCTGCCTGATCCTCC
AAATCACCACAGGACTATTCCTAGCCATG*CACTACTCACCA
GACGCCTCAACCGCC 
*G-A in subjects #1 and #51 
 
F3-R3 
 
mtDNA-73 bp 
 
13699-13771 
AAACGCCTGGCAGCCGGAAGCCT1A2TTCGCAGGATTTCTCA
TTACTAACAACATTTCCCCCGCATCCCCCTTCC 
1Deletion in subjects #80 and #93 
2A-T in all samples 
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